These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Treatment of hyponatremia: the role of lixivaptan. Liamis G; Filippatos TD; Elisaf MS Expert Rev Clin Pharmacol; 2014 Jul; 7(4):431-41. PubMed ID: 24766294 [TBL] [Abstract][Full Text] [Related]
8. Use of tolvaptan in patients with hyponatremia due to heart failure: initial experience. Rodríguez-de Muñoz YM; Sánchez-Lázaro IJ; Almenar-Bonet L; Martínez-Dolz L; Rodríguez-Serrano M; Salvador-Sanz A Rev Esp Cardiol (Engl Ed); 2013 Apr; 66(4):319-21. PubMed ID: 24775629 [No Abstract] [Full Text] [Related]
9. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of tolvaptan in patients hospitalized for heart failure with refractory hyponatremia. Clinical experience in daily practice. Salterain-Gonzalez N; Esteban-Fernández A; García-López M; Lavilla-Royo FJ; Gavira-Gómez JJ Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):503-4. PubMed ID: 24776057 [No Abstract] [Full Text] [Related]
11. Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients. Lin TE; Adams KF; Patterson JH Heart Fail Clin; 2014 Oct; 10(4):607-20. PubMed ID: 25217436 [TBL] [Abstract][Full Text] [Related]
12. Hyponatremia now--a goldmine or a dead end? Gross P Adv Clin Exp Med; 2012; 21(5):559-61. PubMed ID: 23356191 [TBL] [Abstract][Full Text] [Related]
15. [The pathway of vasopressin as a pharmacological target in nephrology: a narrative review]. Recupero M; Fulignati P; Naticchia A; D'Alonzo S; D'Ascenzo F; Costanzi S G Ital Nefrol; 2018 Dec; 35(6):. PubMed ID: 30550035 [TBL] [Abstract][Full Text] [Related]
16. The use of vasopressin receptor antagonists in hyponatremia. Khanna A; Menon MC Curr Opin Investig Drugs; 2010 Sep; 11(9):1007-14. PubMed ID: 20730695 [TBL] [Abstract][Full Text] [Related]
17. A snake toxin as a theranostic agent for the type 2 vasopressin receptor. Droctové L; Lancien M; Tran VL; Susset M; Jego B; Theodoro F; Kessler P; Mourier G; Robin P; Diarra SS; Palea S; Flahault A; Chorfa A; Corbani M; Llorens-Cortes C; Mouillac B; Mendre C; Pruvost A; Servent D; Truillet C; Gilles N Theranostics; 2020; 10(25):11580-11594. PubMed ID: 33052234 [No Abstract] [Full Text] [Related]
18. A history of diabetes insipidus: paving the road to internal water balance. Eknoyan G Am J Kidney Dis; 2010 Dec; 56(6):1175-83. PubMed ID: 20888099 [TBL] [Abstract][Full Text] [Related]
19. Vasopressin-receptor antagonist therapy in patients with hyponatraemia. Vachharajani T; Vachharajani V Br J Hosp Med (Lond); 2007 Jul; 68(7):367-72. PubMed ID: 17663307 [TBL] [Abstract][Full Text] [Related]
20. New horizons in the pharmacologic approach to hyponatremia: the V2 receptor antagonists. Palmer BF J Hosp Med; 2010; 5 Suppl 3():S27-32. PubMed ID: 21157907 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]